MedTrace Logo

Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)

NCT03873337 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-09-13

Study results available
· View outcomes & findings →

Summary

Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our intervention when delivered via telehealth in a single group, within-subjects design.

Conditions

  • Tobacco Use
  • Tobacco Smoking
  • Tobacco Use Cessation
  • Tobacco Use Disorder
  • Schizophrenia
  • Schizoaffective Disorder

Interventions

BEHAVIORAL

Persistence Targeted Smoking Cessation in SMI (PTSC-S)

All participants will receive 8 weeks of persistence focused smoking cessation counseling delivered via telehealth

DRUG

Nicotine patch

All participants will receive 10 weeks of nicotine patch

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Marc L Steinberg, Ph.D. · Rutgers Robert Wood Johnson Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2022-01-10
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03873337 on ClinicalTrials.gov